Details:
Alhemo™ (concizumab) is the first anti-TFPI (Tissue Factor Pathway Inhibitor) approved by health canada for the treatment for people living with Hemophilia B in patients over the age of 12.
Lead Product(s): Concizumab
Therapeutic Area: Genetic Disease Product Name: Alhemo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023